Indefinite Delivery Contract 75D30121D11354

Award Date 6/25/21
Last Date to Order 6/30/22
Federal Agency
CDC Pittsburgh
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under a competitive solicitation to purchase standard adult vaccines. The contracts have a one year period of performance from July 1, 2022 to June 30, 2023 and a combined potential value of $85.6 million. Merck Sharp & Dohme LLC was awarded one of these contracts as the prime contractor. The contracts enable the CDC to order 12 types of adult vaccines for delivery within 15 business days....
The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) awarded an indefinite-delivery, indefinite-quantity (IDIQ) contract to Merck Sharp & Dohme LLC, doing business as Merck, for the supply of various adult vaccines. The contract has a potential value of $87,753,075 and a period of performance from July 1, 2023 through June 30, 2024. The vaccines will be delivered within 15 business days of order receipt and shipped FOB...
The Centers for Disease Control and Prevention (CDC) has awarded a multiple-award Indefinite Delivery Contract (IDC) valued up to $69,520,654.32 to Merck Sharp & Dohme LLC, doing business as Merck, for the supply of various adult vaccines. The contract has a period of performance from July 1, 2024 to June 30, 2025 and does not involve any set-aside designations. The IDC requires Merck, as a pharmaceutical manufacturer, to provide a wide range of adult vaccines including Hepatitis A,...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under a competitive solicitation to purchase standard adult vaccines. The contracts hold a potential value of $102.6 million and require the awarded vendors to provide 13 vaccines to support immunization programs administered by state and local health authorities pursuant to Section 317(j) of the Public Health Service Act. Vaccines include hepatitis A and B, pneumococcal, tetanus/diphtheria, herpes...
The Centers for Disease Control and Prevention awarded multiple indefinite-delivery, indefinite-quantity contracts valued at up to $25,350,000 to supply adult vaccines for the period of July 1, 2023 through June 30, 2024. The prime contractor is VBI Vaccines (Delaware) Inc. The contracts aim to procure minimum and maximum quantities of 12 adult vaccines, including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles, mumps and rubella,...
The Centers for Disease Control and Prevention awarded multiple indefinite-delivery, indefinite-quantity contracts to Pfizer Inc. for the delivery of various adult vaccines. The contracts have a one year period of performance from July 1, 2022 to June 30, 2023 and a combined potential value of $62.2 million. Through these contracts, Pfizer will provide 12 standard adult vaccines to the CDC including hepatitis A & B, pneumococcal, tetanus/diphtheria, herpes zoster, Tdap, MMR, meningococcal,...
The Centers for Disease Control and Prevention (CDC) has awarded an Indefinite Delivery Contract (IDC) to Merck Sharp & Dohme LLC, doing business as Merck, for the supply of up to 23 standard pediatric vaccines. The $3.301 billion contract will run from April 1, 2022 through March 31, 2023, supporting the CDC's Immunization Awardees and the Vaccines for Children program under Section 317(j) of the Public Health Service Act. The vaccines being procured include a wide range such as DTaP, Hep...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services, a civilian agency, to Merck Sharp & Dohme Corp. The contract, which has a ceiling value of $129,202,465.56, is for the delivery of adult vaccines under the 2010-2011 Adult Vaccine Contract program. The contract has a period of performance from July 1, 2010 to June 30, 2011 and was not set aside for any specific socioeconomic category. It is a multiple award...
The Centers for Disease Control and Prevention (CDC) has awarded Pfizer Inc. an Indefinite Delivery Contract (IDC) for the supply of various adult vaccines to support immunization programs under Section 317(j) of the Public Health Service Act. The $103,060,230.33 contract, which runs from July 1, 2023 to June 30, 2024, covers a range of vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles-mumps-rubella, meningococcal...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts to Sanofi Pasteur Inc. for the procurement of adult vaccines. The contracts have a potential value of $39.08 million to supply 13 standard adult vaccines over a one year period from July 1, 2021 through June 30, 2022. Vaccines will be delivered within 15 business days of order to support immunization programs in 50 state health departments and large cities, as provided under Section 317(j) of the Public...

The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts to Merck Sharp & Dohme LLC for adult vaccines. The contracts have a potential value of $83,485,760 and a period of performance from July 1, 2021 to June 30, 2022. Merck will provide 13 standard adult vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus/diphtheria toxoids, herpes zoster, measles/mumps/rubella, meningococcal conjugate, human papillomavirus, and varicella. Delivery must be within 15 business days to locations directed by the CDC throughout the United States to support state health departments and large city immunization programs.

The original solicitation sought contracts to purchase the 13 adult vaccines in minimum quantities for the CDC's National Center for Immunization and Respiratory Diseases. The vaccines will be used to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. No set-aside was used. Proposals were due by April 19, 2021 for contracts running from July 1, 2021 through June 30, 2022. The purpose of the contracts is to provide CDC awardees with access to the stated vaccines to support public health efforts to expand adult immunization rates across the country.

Generated 3/1/24, 9:13 AM